Wael A. Alanazi, PhD

Email: waalanazi@ksu.edu.sa

Dept. of Pharmacology & Toxicology

College of Pharmacy

King Saud University

P.O. Box 2457, Riyadh, 11451, Saudi Arabia



EDUCATION:

• Ph.D. in Pharmacology, Department of Basic Pharmaceutical Science, College of Pharmacy, University of Louisiana at Monroe. (December 2016).
• B.S. Pharmaceutical Sciences, College of Pharmacy, King Saud University (KSU), Riyadh, Saudi Arabia. (January 2011).

WORK HISTORY:

• The head of the Academic Affairs Committee, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. (October 2019- Present).
• The head of the Teaching Load Committee, Department of Pharmacology and Toxicology, King Saud University, Riyadh, Saudi Arabia. (January 2019- Present).
• Assistant Professor, Department of Pharmacology and Toxicology, King Saud University, Riyadh, Saudi Arabia. (February 2017- Present).
• Researcher Assistant, Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Louisiana, USA. (January 2013- December 2016).
• Teaching Assistant, Department of Pharmacology and Toxicology, King Saud University, Riyadh, Saudi Arabia. (December 2011- February 2017).
• Drugs Evaluator, Product Evaluation and Standard Setting Executive Directorate, Drug Sector at Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia. (August 2011- December 2011).

EXPERIENCES:

• Teaching Experience: Teaching different subjects related to biochemistry, pharmacology and toxicology for the undergraduate and graduate students.
  • Pharmacology I & III for undergraduate pharmacy students
  • Dental Pharmacology I for undergraduate dental medicine students
  • PharmD Training course for PharmD students
  • Toxicology of Drug of Abuse for master pharmacy students
  • Advanced Pharmacology II for master pharmacy students
  • Biochemical Toxicology for master pharmacy students
  • Physiological Chemistry for master pharmacy students
  • Drug Discovery and Development for doctoral pharmacy students
• Research Experience:
  • Extensive research experiences in detection the molecular mechanisms of diabetes in causing cardiovascular and renal complications.
  • Developing hypoglycemic and hyperglycemic animal models for acute and chronic in vivo studies.
  • Adaptation advanced techniques such as:
    • Renal Microdialysis Technique for interstitial fluid sampling to identify the local production of different molecules that associated with the complications of hypoglycemia and/or hyperglycemia.
    • Electron Paramagnetic Resonance (EPR) Spectroscopy for quantification of free radicals production during diabetes-induced oxidative stress studies.
  • Demonstrated expertise in:
    • Renal clearance evaluation using IL943 Automatic Flame Photometer
    • Blood cell counter PCE-210N
    • Enzyme-linked immunosorbent assay (ELISA) and Enzyme immune assay (EIA)
    • Real-time polymerase chain reaction (RT-PCR)
    • Western blot analysis for determination of protein expression.
    • Handling rodents and administering drugs through intra peritoneal, subcutaneous and oral routes.
    • Measuring the blood pressure in different rodent models in the presence or absence of anesthesia.
    • Rodent surgeries like catheterization of carotid artery, jugular vein, urinary bladder and artery for plasma collection and drug administration.
    • Bio analysis of various biological matrices encompassing plasma and tissues
    • Softwares such as Hatteras Instruments Blood Pressure Analysis System, BIOPAC systems MP150, GraphPad Prism®, GraphPad Instat and Gen 5™ Microplate Data Collection & Analysis Software.

INTERNSHIPS:

• Internship, Security Forces Hospital. Riyadh, Saudi Arabia. (August 2010- October 2010).
• Internship, Pfizer Company. Riyadh, Saudi Arabia. (July 2010- August 2010).
• Internship, Community Pharmacy (Health House Pharmacies). Riyadh, Saudi Arabia. (July 2009- September 2009).

GRANTS & FUNDING:

• Research Project Support Initiative by Prince Naif Bin AbdulAziz Health Research Center
• Raed Program grant by King Saud University for one year
• Funding for Faculty of Pharmacy by King Saud University
• Principal Investigator for undergraduate research projects

PUBLICATIONS:

• Alasmari AF, Ali N, Alasmari F, Alanazi WA, AlShammari M, Al-Harbi N, AlHoshani A, As Sobeai H, AlSwayyed M, AlAnazi M & AlGhamdi N. Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-kB signaling pathways. Saudi Pharmaceutical Journal. 2020, 28, 509-518.
• Alanazi WA. Role of Carnitine on Hematological Parameters and Attenuation of Cardiac (Pro)renin Receptor and Caspase-3 Expression in Hypoglycemia-induced Cardiac Hypertrophy. International Journal of Pharmacology. 2020, 16, 191-200.
• Nadeem A, Ahmad SF, Al-Harbi NO, El-Sherbeeny AM, Alasmari AF, Alanazi WA, Alasmari F, Ibrahim KE, Al-Harbi MM, Bakheet SA & Attia SM. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells. Int Immunopharmacol. 2020, 80, 106215.
• Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Al-Mazroua HA, Khan MR, Alasmari AF, Alanazi WA, As Sobeai HM & Attia SM. The histamine-4 receptor antagonist JNJ7777120 prevents immune abnormalities by inhibiting RORγt/T-bet transcription factor signaling pathways in BTBR T+ Itpr3tf/J mice exposed to gamma rays. Mol Immunol. 2019, 114, 561-570.
• Nadeem, A, Ahmad SF, Al-Harbi NO, Al-Harbi MM, Ibrahim KE, Kundu S, Attia SM, Alanazi WA & AlSharari SD. Inhibition of spleen tyrosine kinase signaling protects against acute lung injury through blockade of NADPH oxidase and IL-17A in neutrophils and γδ T cells respectively in mice. Int Immunopharmacol. 2019, 2, 39-47.
• Alasmari F, Al-Asmari AF, Alanazi WA, Alshammari M & Alhazzani K. Neuro-inflammatory cytokines induce amyloid beta neurotoxicity through modulating amyloid precursor protein levels/metabolism. Biomed Res Int. 2018, 8 pages.
• Imam F, Al-Harbi NO, Al-Harbi MM, Ansari MA, Al-Asmari AF, Ansari MN, Al-Anazi WA, Bahashwan S, Almutairi MM, Alshammari M, Khan MR, Alsaad AM & Alotaibi MR. Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways. Pharmacol Rep. 2018, 70, 993-1000.
• Ahmad SF, Ansari MA, Nadeem A, Bakheet SA, Alzahrani MZ, Alshammari MA, Alanazi WA, Alasmari AF & Attia SM. Resveratrol attenuates pro-inflammatory cytokines and activation of JAK1-STAT3 in BTBR T+ Itpr3tf/J autistic mice. Eur J Pharmacol. 2018, 829.
• Alotaibi MR, Hassan ZK, Al-Rejaie SS, Alshammari MA, Almutairi MM, Alhoshani AR, Alanazi WA, Hafez MM & Al-Shabanah OA. Characterization of Apoptosis in a Breast Cancer Cell Line after IL-10 Silencing. Asian Pac J Cancer Prev. 2018, 19, 777-783.
• Al-Harbi NO, Nadeem A, Ahmad SF, Alotaibi MR, AlAsmari AF, Alanazi WA, Al-Harbi MM & El-Sherbeeny AM, Ibrahim KE. Short chain fatty acid, acetate ameliorates sepsis-induced acute kidney injury by inhibition of NADPH oxidase signaling in T cells. Int Immunopharmacol. 2018, 58, 24-31.
• Fakhruddin S, Alanazi WA, Alhamami HN, Briski KP, Jackson KE. Hyperglycaemia induced by chronic i.p. and oral glucose loading leads to hypertension through increased Na+ retention in proximal tubule. Exp Physiol. 2017
• Almutairi MM, Alanazi WA, Alshammari MA, Alotaibi MR, Alhoshani AR, Al-Rejaie SS, Hafez MM, Al-Shabanah OA. Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model. BMC Complement Altern Med. 2017, 17, 472.
• Fakhruddin S, Alanazi WA & Jackson KE. Development of a chronic hyperglycemic and hypertensive rat model through repetitive Intraperitoneal and oral glucose loading.  International Journal of Current Research 2017, 9, 48786-48793.
• Fakhruddin S, Alanazi WA & Jackson KE. Diabetes-induced reactive oxygen species (ROS): Mechanism of their generation and role in Renal Injury. Journal of Diabetes Research 2017, 30 pages.
• Alanazi WA, Fakhruddin S & Jackson KE. Microdialysis Sampling of Renal Interstitial Fluid in Acute Studies. International Journal of Biology 2016, 8, 69-79.
• Alanazi WA, Fakhruddin S & Jackson KE. The Role of Recurrent Insulin-Induced Hypoglycemia on Renal Prostanoid Production. Annual Research & Review in Biology 2016, 11, 1-9.
• Alanazi WA, Fakhruddin S & Jackson KE. Acute Angiotensin II Infusion Promotes Local Production of Prostaglandin E2 and Reactive Species in the Renal Cortex. Innovative Journal of Medical & Health Science 2016, 146-151.
• Alanazi WA, Uddin MB, Fakhruddin S & Jackson KE. Recurrent Insulin-Induced Hypoglycemia enhances AngII and COX2 leading to Renal PRR Expression and Oxidative Stress in the Heart and Kidney. International Journal of Medicine 2017, 5, 71-78.
• Prathipati P, Alanazi WA, Fakhruddin, Jackson DW & Jackson KE. Role of interstitial angiotensin II and ATP in mediating renal injury induced by recurrent insulin induced hypoglycemia. Annual Research & Review in Biology 2015, 6, 328-36.

CONFERENCES:

• Alanazi WA, Fakhruddin S & Jackson KE. Angiotensin II Induces Prostaglandin E2 Production and Oxidative Stress in the Renal Cortex. Experimental Biology (EB) Meeting, Apr. 2nd, 2016. San Diego, CA.
• Fakhruddin S, Alanazi WA & Jackson KE. Hyperglycemia Induced by Chronic Intraperitoneal and Oral Glucose Loading Leads to Hypertension through Proximal Tubule Oxidative Stress- and Angiotensin II-Mediated Na+-Retention. Experimental Biology (EB) Meeting, Apr. 22nd, 2017. San Diego, CA.